anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a powdery far infrared radiating material prepared by press crushing a lava with a press, or the like, and pulverizing the resultant material with various kinds of pulverizers. SOLUTION: This powdery far infrared radiating material 1 is obtained by press crushing a mass of a lava with a press, or the like, and further pulverizing the resultant material into a powdery form with various kinds of means. The resultant powdery far infrared radiating material 1 is then housed in a container 2 having air permeability or added to a coating material, a clay, a paper, a synthetic resin, a nonwoven fabric or a cosmetic such as a pack material. The material 1 prepared by pulverizing the lava into the powdery form is designed to be readily added and mixed with the cosmetic, coating material, clay, paper, a rubber, the synthetic resin, nonwoven fabric, glass, or the like. Thereby, antimicrobial actions, metabolic functions and cleaning actions possessed by the far infrared rays can effectively be exhibited.  The antimicrobial actions are imparted to the cosmetic in addition to the essential actions possessed by the cosmetic especially by mixing thereof with the cosmetic. Effects of metabolic functions and cleaning actions for daily living can be produced by mixing thereof with a coating material and coating a building with the resultant material, mixing with the clay, paper, rubber, synthetic resin, nonwoven fabric, glass, or the like, and providing various kinds of living necessaries.
FIELD: cattle breeding. SUBSTANCE: after 0-24 h of piglet weaning, i. e. at the initial lactation stage serum gonadotropin of mare in foal is administrated by subcutaneous injection to sows at the dose 1500-2000 I.U. per a head. Then after 50-60 h surfagon (luliberin) is administrated intramuscularly additionally at a single dose 5-10 mcg per a head. Use of method provides to decrease agalactosis in sows by 10.4%. Serum gonadotropin of mare in foal is administrated by subcutaneous injection at the dose 1500-1800 I. U. per head to sows, and after 24 h surfagon is administrated additionally by intramuscular injection at the dose 5-10 mcg per a head. EFFECT: agalactosis prevention, dairy productivity stimulation. 1 tbl
Measurable residual disease (MRD) is a powerful prognostic factor of relapse in acute myeloid leukemia (AML). We applied the single-cell RNA sequencing to bone marrow (BM) samples from patients with (n=20) and without (n=12) MRD after allogeneic hematopoietic stem cell transplantation. A comprehensive immune landscape with 184,231 cells was created. Compared with CD8+ T cells enriched in the MRD-negative group (MRD-_CD8), those enriched in the MRD-positive group (MRD+_CD8) showed lower expression levels of cytotoxicity-related genes. Three monocyte clusters (i.e., MRD+_M) and three B-cell clusters (i.e., MRD+_B) were enriched in the MRD-positive group. Conversion from an MRD-positive state to an MRD-negative state was accompanied by an increase in MRD-_CD8 clusters and vice versa. MRD-enriched cell clusters employed the macrophage migration inhibitory factor pathway to regulate MRD-_CD8 clusters. These findings revealed the characteristics of the immune cell landscape in MRD positivity, which will allow for a better understanding of the immune mechanisms for MRD conversion.
PURPOSE:To improve the adhesiveness to the skin, the spreadability, and the ultraviolet and infrared screening effect by coating the surface of flaky base material particles with a metallic oxide mixture comprising TiO2 and ZrO2 at a specified molar ratio. CONSTITUTION:An aqueous suspension of flaky base material particles (e.g. talc) having a particle diameter of 0.5-100mum is mixed with a mixture of an aqueous solution of 5-35wt.% Ti compound (e.g. TiCl3) and an aqueous solution of 5-35wt.% Zr compound [e.g. Zr(SO4)2] at an equivalent ratio of the Zr compound to the Ti compound of 0.1 to 1.5; an aqueous solution containing 5-35wt.% alkali hydroxide (e.g. NaOH) or alkali carbonate (e.g. Na2CO3); and if necessary, an aqueous solution containing Ba ions (e.g. BaCl2). While the pH of the mixture is adjusted to 1.5 to 2.5, a reaction is effected to deposit a hydrated TiO2 and a hydrated ZrO2 on the surfaces of the base material particles. The obtained solid product is separated, dried at 105-110 deg.C, and baked, thus giving a pigment which comprises the flaky base material particles having the surfaces coated with 20-60wt.% metallic oxide mixture comprising TiO2 and ZrO2 at a molar ratio of (10:1) to (10:15).
548,784. Treating diseases with light. MARSHALL, S. Aug. 21, 1941. No. 10646. [Class 81 (ii)] An appliance for the treatment of rheumatism and the like and for promoting the growth of hair comprises a substance for transmitting daylight of artificial heat made from glue which, after being melted and allowed to cool a little, is sprayed with a solution of bichromate of potash. The substance is allowed to harden and may be mounted in a handle or used as a covering for windows.
Although the relationship between hypertension and hyperuricemia is widely recognized, there is still a relative lack of research on prehypertensive individuals and the individual associations of systolic and diastolic blood pressure with the risk of hyperuricemia. From 2011 to 2016, we conducted a study on 53,323 individuals at Wuhu City Hospital in China. Based on initial blood pressure readings, participants were categorized into normal, prehypertension, or hypertension groups. We used Cox regression to analyze the associations with baseline factors. In subgroup analyses, systolic and diastolic pressures were treated as continuous variables, and their relationship with the risk of hyperuricemia was examined using restricted cubic spline analysis. The risk increased in the prehypertension and hypertension groups compared to the normal blood pressure group, with hazard ratios of 1.192 and 1.350, respectively. For each unit increase in blood pressure, the risk of hyperuricemia rose by 0.8% (systolic) and 0.9% (diastolic), especially when blood pressure levels exceeded 115/78 mmHg. Additionally, we observed that factors such as gender, alcohol consumption habits, obesity, and dyslipidemia might further influence this association. These findings emphasize the importance of early risk assessment and intervention in these patient populations in clinical practice.
PURPOSE:An ointment base for the skin, prepared by adding a very small  amount of a perfume to incrustations of hot-spring water naturally occurring in  large amounts and an extract of a plant of the genus aloe, capable of cleaning  the surface of the skin in a short time, showing the skin beautifying effects, and preparable at a low cost without side effects. CONSTITUTION:An ointment base prepared by adding a very small amount of a perfume to a kneaded mixture of incrustations of hot-spring water with an extract from a plant of the genus Aloe. The resultant mixture prepared by kneading the incrustations of hot-spring water with the extract from a plant of the genus Aloe and vaseline is rubbed fully into an affected part of athlete's foot, insect bites, chilblain, cuts, hemorrhoids, etc. to alleviate the pain or itching. The surface of the skin is smoothed, and the skin beautifying effect can be produced by repeating the pack of the base diluted with a solvent, e.g. vaseline, on the roughened part of the skin, e.g. a pimple. EFFECT:The pharmacological effect of the hot spring is obtained at a low cost though indirectly.
Accurate assessment of post-stroke deficits is crucial in translational research. Recent advances in machine learning offer precise quantification of rodent motor behavior post-stroke, yet detecting lesion-specific upper extremity deficits remains unclear. Employing proximal middle cerebral artery occlusion (MCAO) and cortical photothrombosis (PT) in mice, we assessed post-stroke impairments via the Staircase test. Lesion locations were identified using 7 T-MRI. Machine learning was applied to reconstruct forepaw kinematic trajectories and feature analysis was achieved with MouseReach, a new data-processing toolbox. Lesion reconstructions pinpointed ischemic centers in the striatum (MCAO) and sensorimotor cortex (PT). Pellet retrieval alterations were observed, but were unrelated to overall stroke volume. Instead, forepaw slips and relative reaching success correlated with increasing cortical lesion size in both models. Striatal lesion size after MCAO was associated with prolonged reach durations that occurred with delayed symptom onset. Further analysis on the impact of selective serotonin reuptake inhibitors in the PT model revealed no clear treatment effects but replicated strong effect sizes of slips for post-stroke deficit detection. In summary, refined movement analysis unveiled specific deficits in two widely-used mouse stroke models, emphasizing the value of deep behavioral profiling in preclinical stroke research to enhance model validity for clinical translation.
The coronal oblique supraclavicular block will be applied to the first group with ultrasound guidance using a 22G 50 mm stimulator needle. 30 ml of bupivacaine (Bupivacaine HCl %0.5) and prilocaine (Priloc HCl %2) 1:1 mixture will be prepared in a way that there will be 5 mcg adrenaline per ml. (14 ml. bupivacaine, 14 ml. prilocaine, 2 ml saline with 5 mcg adrenaline per ml.) Intermittent negative aspiration will be performed during all procedures to detect possible vascular puncture.
There is provided a petrolatum substitute. The petrolatum substitute preparation comprises 1-20 wt % of at least one oil thickening agent, 7-40 wt % of at least one structuring agent, 0.5-10 wt % of at least one phytosterol or ester thereof, and 30-92 wt % of at least one emollient, wherein the preparation has a melting point of 35° C. or more. The petrolatum substitute preparation can be used in essentially all applications where petrolatum is used today. The substitute can be made renewable and the use of over-exploited natural products is minimized. The preparation is less irritant and has excellent moisture barrier properties when applied to human skin. Further it is less energy consuming to manufacture.
Cobimetinib, 60mg po daily. 28 day cycle; day 1-21 60mg daily, day 22-28 rest period.
The invention relates to an externally-applied traditional Chinese medicine for improving exophthalmos, and a preparation method and an application of the externally-applied traditional Chinese medicine. The externally-applied traditional Chinese medicine comprises the following raw materials, by weight: 15-20 parts of rhinoceros horn, 7-15 parts of bear gall, 7-15 parts of cow-bezoar, 7-20 parts of saffron, 5-11 parts of wolfberry, 5-11 parts of abalone shell, 5-11 parts of pangolin scale, 3-7 parts of spatholobus stem, 3-7 parts of panax notoginseng, 3-7 parts of entada phaseoloides, 10-30 parts of spirifer, 5-10 parts of rhizoma alismatis, and 1-3 parts of musk. The externally-applied traditional Chinese medicine is adhered to corresponding acupoints, without hair, at the head, and can improve exophthalmos, the visual acuity of human eyes, and eye functions. The beneficial effects of the externally-applied traditional Chinese medicine are that human eye functions are improved; the visual acuity is improved; the recent effect is achieved instantly; and the long-term effect is stable. The surgical risk is eliminated; and perennial acupuncture therapy and medicine administration are omitted. Venation dredging is fully utilized to develop the natural repair ability of the human body. The medicine is not limited by age, and conventional situations of exophthalmos due to glasses wearing of short-sighted persons over sixteen and irrecoverable shortsightedness are avoided.
The present invention relates to a tumor control pill which is made from three types of traditional Chinese medicines. The tumor control pill overcomes the cancer through perennial research and treatment, has significant curative effect on cancerous patients for early recovering by traditional Chinese medicines, and provides benefits for the cancerous patients. The tumor control pill is economic, is suitable for a plurality of cancerous patients of wage earners to admit, and simultaneously has good effect after the external application of ointment (secret recipe handed down from generation). The tumor control pill can eliminate tumors of mammary cancer, laryngeal cancer, lymphocyte cancer and bone cancer, and alleviate pain. The supporting treatment method can perform the function of external attack. Sal ammoniac has the functions on perforating the tumors of smooth muscle tumors, larynxs, gullets, stomachs, uteruses, bowels, intestines, intestinal walls, etc., killing the cancer cells, causing the cancer cells to be apoptotic, removing the corrosive and rotted meat, promoting the regeneration of tissues, detoxicating and eliminate swelling. Chinese stellera root can reinforce the peristalsis of small bowels and treat the constipation, the experiment mouse has pain threshold of 20 to 50%, and the Chinese stellera root has no side effect on livers, kidneys, digestive functions and hemopoietic systems. Liquoric root with stir-frying has sweet in taste, can proportion bias of various medicaments to well perform the functions, and can be used for invigorating spleens, replenishing qi, moistening lungs for arresting cough, and detoxicating. The Chinese stellera root and the sal ammoniac are combined to use, the drug effect is enhanced, the cancer cells are perforated and killed, the cancer cells are apoptotic, and the liquoric root is simultaneously used for compensating for the defects of the Chinese stellera root and the sal ammoniac. The three types of traditional.
The invention provides a dampness-eliminating itching-relieving traditional Chinese medicine preparation. The dampness-eliminating itching-relieving traditional Chinese medicine preparation comprises fructus kochiae, fructus cnidii, white muscardine silkworm, cortex dictamni, herba artemisiae scopariae, schizonepeta spike, herba patriniae, radix angelicae dahuricae and borneol, and is prepared by the following steps of grinding the active ingredients into 60 meshes for later use through a grinder; and heating and melting glycerinum, albolene and parogen as an oil phase, then slowly adding the ground ingredient powder into the oil, and packing into ten boxes after being condensed. The Chinese herbal medicines have the effect of inhibiting dermatophyte, trichophyton concentricum and trichophyton schoenleinii. The dampness-eliminating itching-relieving traditional Chinese medicine preparation has the effects of inhibiting bacteria such as staphylococcus aureus, hemolytic streptococcus, escherichia coli, pseudomonas aeruginosa and proteusbacillus vulgaris. Therefore, the dampness-eliminating itching-relieving traditional Chinese medicine preparation has a good effect on treating dermatonosis. The dampness-eliminating itching-relieving traditional Chinese medicine preparation has the characteristics of having no hormone and fewer toxic and side effects as being prepared by taking pure Chinese herbal medicines, treating both symptoms and root causes, being obvious in curative effect; the clinical symptoms are fast to disappear, medicament dependence is not caused, and no replase phenomenon after being healed does not exist.
A method of treating stroke in a patient who has undergone a stroke comprising administering at least 2 million suitable neuronal cells to at least one brain area involved in the stroke. The method comprises the step of using a twist drill or a burr to form a hole in the skull through which the cells could be administered. Exemplary cells are hNT neuronal cells, HCN-1 cells, fetal pig cells, neural crest cells, neural stem cells, or a combination thereof. Also disclosed herein is a pharmaceutical composition of 95 % pure hNT neuronal cells, which composition further includes a vial containing PBS and human neuronal cells. This vial is provided in a container with liquid nitrogen, whereby the composition is frozen and maintained at -170 °C before use. Also disclosed are methods of improving speech, cognitive, sensory, and motor function in a person who has experienced brain damage which interferes with function by administering a sterile composition of a sufficient number of neuronal cells or neural stem cells to the damaged area. Also disclosed is a method of replacing central nervous cells lost to neurodegenerative disease, trauma, ischemia or poisoning.
The investigators will define major usability issues with different versions of functional prototypes of eMOM GDM application developed in the project before moving to phase 2 of the study. General pregnant women (n=up to 30) will use the available version of the application for one week, and afterward the general pregnant women will fill out a web form of usability of the application after the application week.
The ultra-wide band rf-enhanced chemotherapy for treatment of cancer and other intracellular diseases provides for increasing drug effectiveness. It also provides a means of treatment of inoperable cancers. The invention uses ultra-wide band short pulses to provide high electric field strength in diseased areas of a patient to induce electroporosis preferentially in the region to be treated by chemotherapy. The effect is to make the interiors of the cells in the affected region open to the chemotherapeutic agent. The treatment can be enhanced in its effectiveness thereby. It also enables treatment with reduced doses of the therapeutic agent and reduces side effects in other areas of the patient through the reduction of the total dosage. The invention makes specific use of the polarization of UWB fields and the very short duration of the pulsed electromagnetic fields induced into the region to be treated to minimize the absorbed rf energy associated with the treatment, making the heating of tissue negligible. It also uses a pulse repetition frequency slow enough to avoid wholesale killing of cells through osmotic shock.
Management of dietary protein intake of the CRF patient represents a critical balance between providing adequate protein to meet nutritional requirements, and limiting protein intake in the hope of slowing or abating the progression of CRF. A number of studies have demonstrated that reduced dietary protein intake can slow the progression of chronic renal failure. Finding effective ways to increase nitrogen retention and decrease urinary nitrogen excretion may help CRF patients maintain a more positive nitrogen balance and lessen the nitrogen load on the kidneys for a given dietary protein intake. Our laboratory has demonstrated that in older men and women, the consequence of adherence to a low protein diet is an accommodation that results in decreased muscle mass, strength,and compromised immune function. We have also demonstrated that when healthy, free living older men and women consume a weight maintenance diet providing the RDA for protein of 0.8 g/kg-1/day-1 for 15 weeks they lose skeletal muscle mass. These data clearly indicate that elderly people have an increased need for dietary protein (compared to young people). Data has also demonstrated that progressive resistance exercise improves nitrogen balance in older healthy individuals as well as in patients with mild to moderate chronic renal failure.
Adult male with primary premature ejaculation. They will receive electroacupuncture at ST36 to treat premature ejaculation.
To collect baseline data on cardiac rehabilitation usage (referrals and completion) in recent post-MI patients with EF \> 35%.To collect data on AMS-derived biometric data (e.g. HR, activity) and arrhythmias, and subject-reported symptoms, beta blocker/ivabradine usage (dose/changes) and cardiovascular events. The participating centers will enroll consenting subjects in a sequential manner to avoid preferential selection of patients to participate in the study. Subjects will be consented by the center study staff, and if eligible will wear the FDA-cleared AMS device for 30-60 days. Subject demographic information and clinical history will be obtained at the time of enrollment. During the study period, the prescribing physician-investigator will be blinded to AMS data. Final subject follow-up will be at 3 months. A sample size of 150 subjects is estimated in order to have 100 subjects with at least 30 days of AMS use for analysis.
In Part B, up to 16 subjects will receive IkT001-Pro and up to 16 subjects will receive 400mg of imatinib mesylate. After a 7 day washout period the subjects will switch to receive the drug they did not previously receive.
PURPOSE:To provide the titled composition containing nicotinic acid ester or isonicotinic acid ester and having improved dermatic permeability and transcutaneous absorbability of a drug, especially a water-soluble drug. CONSTITUTION:The objective composition contains the compound of formula I of formula II (R and R<1> are 1-4C alkyl). The content of the compound is 0.01-20wt%, preferably 0.2-10wt% based on the total amount of the base. The composition is preferably added further with a hydrophobic compound such as an aliphatic alcohol, aliphatic hydrocarbon, alcohol ester of aliphatic carboxylic acid, ether, ketone, etc. The ratio of the above compound to the hydrophobic compound is preferably 75:25-99:1. A drug is administered in the presence of the above composition, however, it is preferable to compound the drug to the composition prior to administration.
Futile recanalization hampers prognoses of ischemic stroke after successful mechanical thrombectomy, hypothetically through post-recanalization perfusion deficits, onset-to-groin delays and sex effects. Clinically, acute multiparametric imaging studies remain challenging. We assessed possible relationships between these factors and disease outcome after experimental cerebral ischemia-reperfusion, using translational MRI, behavioral testing and multi-model inference analyses. Male and female rats (N = 60) were subjected to 45-/90-min filament-induced transient middle cerebral artery occlusion. Diffusion, T2- and perfusion-weighted MRI at occlusion, 0.5 h and four days after recanalization, enabled tracking of tissue fate, and relative regional cerebral blood flow (rrCBF) and -volume (rrCBV). Lesion areas were parcellated into core, salvageable tissue and delayed injury, verified by histology. Recanalization resulted in acute-to-subacute lesion volume reductions, most apparently in females (n = 19). Hyperacute normo-to-hyperperfusion in the post-ischemic lesion augmented towards day four, particularly in males (n = 23). Tissue suffering delayed injury contained higher ratios of hypoperfused voxels early after recanalization. Regressed against acute-to-subacute lesion volume change, increased rrCBF associated with lesion growth, but increased rrCBV with lesion reduction. Similar relationships were detected for behavioral outcome. Post-ischemic hyperperfusion may develop differentially in males and females, and can be beneficial or detrimental to disease outcome, depending on which perfusion parameter is used as explanatory variable.
Participants will be screened based on FGFRi CTA to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (no prior treatment with anti-PD-\[L\] 1 agent) will receive pembrolizumab 200 mg as a 30-minute intravenous infusion once every 3 weeks, until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustments are based on observed toxicities. Participants who enter in LTE phase will continue to receive the pembrolizumab until 2 years after the first dose of pembrolizumab (at start of study) or until the participant can commercially receive pembrolizumab within the local healthcare system, whichever comes first.